skip to main content

    Updated Visitor Guidelines

 

MENU

 

What is Treated

CAR T-cell Therapy has been approved by the U.S. Food and Drug Administration for:

Using one's cells to attack and treat cancer continues to grow. Cellular therapy and in particular CAR T-cell therapy offers new opportunities to adult and pediatric patients with blood cancers like leukemia and lymphoma. Dr. Monalisa Ghosh, Rogel Cancer Center oncologist talks about these treatments and and the future of cellular therapy.   CAR T-cell and Cellulary Therapy podcast transcript

    1) To treat adult patients with relapsed or refractory large B-cell lymphomas whose cancer has progressed after receiving at least two prior treatment regimens.

    2) To treat children and young adults up to age 25 with B-cell acute lymphoblastic leukemia (ALL) that does not respond to treatment or has relapsed two or more times.

Why choose the University of Michigan for CAR T-cell Therapy?

The University of Michigan has been on the front lines of this therapy for the past several years, participating in the pivotal trials that led to the approval of the first FDA-approved CAR T-cell therapy in 2017. Our cancer center is the first site in Michigan to offer both currently FDA-approved CAR T-cell therapies: Kymriah™ (Novartis) and Yescarta™ (Kite).

Michigan Medicine has one of the leading transplant programs in the country, recognized for our innovative clinical research and clinical care. Our clinicians have 30 years of cell therapy experience and extensive experience managing side effects that can occur from this therapy.

As a research institution, we’re always looking for new ways to help patients through clinical research. Our multidisciplinary team of specialists is working to find new uses for this technology, and clinical trials are in development for multiple other blood and solid tumor cancers.